Zobrazeno 1 - 10
of 337
pro vyhledávání: '"Richard A. Burt"'
Autor:
Richard K. Burt, Paul Tappenden, Roumen Balabanov, Xiaoqiang Han, Kathleen Quigley, John A. Snowden, Basil Sharrack
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: Intravenous immunoglobulin (IVIG) is effective as standard first line therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but some patients remain dependent on its long-term use. Recently, we have reported that a
Externí odkaz:
https://doaj.org/article/07eb9f1b2a194530ae78ae77c0ee2735
Autor:
Milton Artur Ruiz, Roberto Luiz Kaiser, Luiz Gustavo de Quadros, Lilian Piron-Ruiz, Tatiana Peña-Arciniegas, Mikaell Alexandre Gouvea Faria, Rubens Camargo Siqueira, Flavio Fontes Pirozzi, Fernanda Soubhia Liedtke Kaiser, Richard K. Burt
Publikováno v:
BMC Research Notes, Vol 10, Iss 1, Pp 1-7 (2017)
Abstract Objective The incidence of adverse events in myeloablative transplant protocols is high in refractory Crohn’s disease; this study used low doses of cyclophosphamide. Fourteen patients were submitted to non-myeloablative autologous hematopo
Externí odkaz:
https://doaj.org/article/f085769beec34e418bed70347afe417a
Autor:
Vilma Dembitz, Hannah Lawson, Celine Philippe, Richard J. Burt, Sophie James, Aoife S.M. Magee, Keith Woodley, Jozef Durko, Joana Campos, Michael James Austin, Ana Rio-Machin, Pedro Casado Izquierdo, Findlay Bewicke-Copley, Giovanny Rodriguez Blanco, Bela Patel, Lori Hazlehurst, Barrie Peck, Andrew Finch, Pedro Cutillas, Jude Fitzgibbon, Mariia Yuneva, Kevin Rouault-Pierre, John Copland, Kamil Kranc, Paolo Gallipoli
Publikováno v:
Blood. 140:3058-3060
Publikováno v:
Journal of Neurology
Objective To investigate the results of real-world application of non-myeloablative autologous HSCT for multiple sclerosis (MS). Methods Between July 2003 and October 2019 at a single center (Northwestern University), 414 patients with relapsing remi
Autor:
Marie Hudson, Pauline Lansiaux, Mianbo Wang, Dominique Farge, Catney Charles, Louis Terriou, Sabine Berthier, Richard K. Burt, Nassim Ait Abdallah, Mathieu Puyade
Publikováno v:
Bone Marrow Transplantation. 56:2259-2267
Two randomised trials (ASTIS, SCOT) of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) versus monthly Cyclophosphamide for severe Systemic Sclerosis (SSc) patients used similar inclusion criteria, but different primary endpoints: event-fre
Autor:
Aditi Dey, Richard J. Burt, Emily A. Cutler, Hermione E. Allen, Ashish Dhir, Kristina Kirschner, Adele K. Fielding
Publikováno v:
Blood. 140:2895-2896
Autor:
Priscila Samara Saran, Lilian Castiglioni, Tainara Souza Pinho, Roberto Luiz Kaiser Junior, Lilian Piron-Ruiz, Luiz Gustavo de Quadros, Richard K. Burt, Milton Artur Ruiz
Publikováno v:
World Journal of Stem Cells
Crohn's disease (CD) is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract. The etiology of CD is unknown; however, genetic, epigenetic, environmental, and lifestyle factors could play an essential role in the
Autor:
Borko Jovanovic, Benjamin H. Freed, Irene Helenowski, Kathleen Quigley, Sanjiv J. Shah, Daniel C. Lee, Indira Arnautovic, Richard K. Burt, Xiaoqiang Han
Publikováno v:
Bone Marrow Transplantation. 56:50-59
We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three reg
Autor:
Kathleen Quigley, Richard K. Burt, Indira Arnautovic, Amy L. Halverson, Robert M. Craig, Xiaoqiang Han, Laura Yun
Publikováno v:
Bone Marrow Transplantation. 55:2343-2346
Autor:
Sarah Aref, Daniel Leongamornlert, Richard K. Burt, Adele K. Fielding, Dina Ahmed Said Aly Okasha, Aditi Dey, Katharine Bailey, Anna Castleton, Rachel J. Mitchell
Publikováno v:
Mol Ther
The mechanism of tumor-selective replication of oncolytic measles virus (MV) is poorly understood. Using a stepwise model of cellular transformation, in which oncogenic hits were additively expressed in human bone marrow-derived mesenchymal stromal c